DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes

Kensuke Kayamori,1,2 Yurie Nagai,2 Cheng Zhong,1 Satoshi Kaito,1 Daisuke Shinoda,1 Shuhei Koide,1 Wakako Kuribayashi,1 Motohiko Oshima,1 Yaeko Nakajima-Takagi,1 Masayuki Yamashita,1 Naoya Mimura,3 Hans Jiro Becker,4 Kiyoko Izawa,4 Satoshi Yamazaki,4,5 Satoshi Iwano,6 Atsushi Miyawaki,6 Ryoji Ito,7 Kaoru Tohyama,8 William Lennox,9 Josephine Sheedy,9 Marla Weetall,9 Emiko Sakaida,2 Koutaro Yokote,2 and Atsushi Iwama1

1Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; 2Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan; 3Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan; 4Division of Stem Cell Biology, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; 5Laboratory of Stem Cell Therapy, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan; 6Laboratory for Cell Function Dynamics, Center for Brain Science, RIKEN, Saitama, Japan; 7Central Institute for Experimental Animals, Kanagawa, Japan; 8Department of Laboratory Medicine, Kawasaki Medical School, Okayama, Japan; and 9PTC Therapeutics Inc, South Plainfield, NJ

Key Points

- DHODH inhibition synergizes with DNA-demethylating agents in the treatment of MDS.
- DHODH inhibition enhances the incorporation of decitabine into DNA in MDS cells.

Dihydroorotate dehydrogenase (DHODH) catalyzes a rate-limiting step in de novo pyrimidine nucleotide synthesis. DHODH inhibition has recently been recognized as a potential new approach for treating acute myeloid leukemia (AML) by inducing differentiation. We investigated the efficacy of PTC299, a novel DHODH inhibitor, for myelodysplastic syndrome (MDS). PTC299 inhibited the proliferation of MDS cell lines, and this was rescued by exogenous uridine, which bypasses de novo pyrimidine synthesis. In contrast to AML cells, PTC299 was inefficient at inhibiting growth and inducing the differentiation of MDS cells, but synergized with hypomethylating agents, such as decitabine, to inhibit the growth of MDS cells. This synergistic effect was confirmed in primary MDS samples. As a single agent, PTC299 prolonged the survival of mice in xenograft models using MDS cell lines, and was more potent in combination with decitabine. Mechanistically, a treatment with PTC299 induced intra-S-phase arrest followed by apoptotic cell death. Of interest, PTC299 enhanced the incorporation of decitabine, an analog of cytidine, into DNA by inhibiting pyrimidine production, thereby enhancing the cytotoxic effects of decitabine. RNA-seq data revealed the marked downregulation of MYC target gene sets with PTC299 exposure. Transfection of MDS cell lines with MYC largely attenuated the growth inhibitory effects of PTC299, suggesting MYC as one of the major targets of PTC299. Our results indicate that the DHODH inhibitor PTC299 suppresses the growth of MDS cells and acts in a synergistic manner with decitabine. This combination therapy may be a new therapeutic option for the treatment of MDS.

Introduction

Myelodysplastic syndrome (MDS) is a clonal bone marrow (BM) disorder characterized by ineffective and clonal hematopoiesis accompanied by morphological dysplasia and variable cytopenia. DNA methyltransferase inhibitors azacitidine and decitabine have been used as chemotherapeutic agents for high-risk MDS. They are chemical analogs of cytidine that have direct cytotoxicity and induce DNA hypomethylation by interfering with DNA methyltransferase. Overall survival has been prolonged in
patients with MDS and acute myeloid leukemia (AML) transformed from MDS. In spite of these therapies, these diseases become uncontrolled in many cases and survival remains suboptimal. Median overall survival is 24.5 months in high-risk MDS patients treated with azacitidine.\(^1\) Allogeneic hematopoietic stem cell transplantation is still considered the only potentially curative option, but is accessible to only a small number of patients because of factors such as advanced age, comorbidities, and donor availability. Therefore, innovative treatment strategies are needed.\(^2\)

Dihydroorotate dehydrogenase (DHODH) catalyzes a rate-limiting step in de novo pyrimidine nucleotide synthesis, the conversion of DHO to orotate. DHODH inhibition was recently described as a potential new approach for treating AML by inhibiting cell proliferation and inducing cell death and the differentiation of diverse AML subtypes.\(^3\) Pyrimidine nucleotides can be generated by de novo synthesis or the salvage pathway in which pyrimidine nucleotides are obtained from the diet. Resting cells typically acquire adequate levels of pyrimidine nucleotides from the salvage pathway. Rapidly proliferating cells, such as leukemia cells, are dependent on the de novo synthesis of pyrimidine nucleotides.\(^4,5\) DHODH inhibitors, such as teriflunomide, bremuran, and vidofludimus, have been considered for use in oncology.\(^6,7\) PTC299 was initially identified as an inhibitor of the translation of VEGFA messenger RNA using a phenotypic screening platform.\(^9\) PTC299 was then subsequently determined to be a potent inhibitor of DHODH as its primary mechanism of action. Inhibition of VEGFA production by PTC299 is a downstream effect of inhibiting de novo pyrimidine synthesis because it can be completely rescued by exogenously added uridine but not by other nucleosides.\(^10\) The clinical development of PTC299 as a potential treatment option for AML was recently initiated (US Food and Drug Administration Clinical Trial No. NCT03761069).

In the present study, we examined the efficacy of DHODH inhibition with PTC299 in MDS cell lines, primary MDS cells from patients, and in xenograft MDS models. Our results indicate that PTC299 suppresses the growth of MDS cells in vitro and in vivo. In addition, we found that PTC299 synergizes with decitabine by enhancing its incorporation into DNA through the inhibition of pyrimidine nucleotide production.

**Materials and methods**

**Cell culture and drug treatment**

HL-60, THP-1, and SKM-1 cell lines were acquired from ATCC. MDS-L and TF-1 cell lines, which were provided by Dr. Kaoru Tohyama (Kawasaki Medical School, Japan) and Toshio Kitamura (The University of Tokyo), respectively, were authenticated by short tandem repeat profiling using a PowerPlex 16 HS system (Promega). Cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich) and 1% penicillin/streptomycin (Gibco). SKM-1 cells were cultured in RPMI supplemented with 20% FBS. MDS-L and TF-1 cells were cultured in the presence of human interleukin-3 (IL-3; 10 ng/mL, BioLegend) and 1 ng/mL of granulocyte-macrophage colony-stimulating factor (GM-CSF; 1 ng/mL, BioLegend), respectively. Stocks of PTC299 (synthesized at PTC Therapeutics) and decitabine (Wako) were prepared in dimethyl sulfoxide (DMSO; Sigma-Aldrich) at concentrations of 3 and 10 mM, respectively. In the growth assays, cells were seeded on 24-well plates in triplicate and treated with graded concentrations of PTC299 and decitabine. Decitabine was added to culture with daily refreshment resulting from the short-half time of this drug. Cells were counted using 0.1% trypan blue dye. MTS viability tests were conducted according to the manufacturer’s instructions (Promega). Synergism was assessed by calculating the proportion of cell growth using CompuSyn software (Combio Syn, Inc.).\(^11\)

**Flow cytometric analysis and apoptosis and cell-cycle assays**

The expression of CD11b and CD38 by cell lines was assessed using fluorochrome-tagged monoclonal antibodies (BD Biosciences). Apoptosis and the cell cycle were examined using an Annexin-V Apoptosis kit and a 5-bromo-2’-deoxyuridine (BrdU) Flow kit (BD Pharmingen) according to the manufacturer’s instructions. Flow cytometric analyses were performed on BD FACS Celesta (BD Bioscience).

**RNA sequencing**

Total RNA was isolated from MDS-L and SKM-1 cells treated with DMSO, 30 nM of PTC299, 200 nM of decitabine, and a combination of both agents using the RNeasy Mini Kit (Qiagen). After reverse transcription, the libraries for RNA-sequencing (RNA-seq) were generated from fragmented DNA with 15 cycles of amplification using a Next Ultra DNA Library Prep Kit (New England BioLabs). After the libraries had been quantified using the TapeStation (Agilent), samples were subjected to sequencing with HiSeq1500 (Illumina) and 61 cycles of the sequencing reactions were performed. RNA-seq raw reads (fastq files) were mapped to a human genome. Gene level counts for fragments mapping uniquely to the human genome were extracted from BAM files. Gene expression values were then calculated as reads per kilobase of exon units per million mapped reads using cufflinks (version 2.2.1). A gene set enrichment analysis (GSEA) was performed based on curated gene sets from the Broad Institute’s molecular signatures database MSigDB.

**Deposition of data**

RNA sequence data were deposited in the DNA Data Bank of Japan (accession number DRA 009271).

**Conditional expression of c-MYC**

MDS cells were transduced with the all-in-one Tet-on inducible lentiviral vector (Ai-LV) for the expression of c-MYC.\(^12\) Transduced cells were purified by cell sorting using green fluorescent protein as a marker. c-MYC expression was induced by the addition of doxycycline.

**AkaBLI system**

In vivo bioluminescence imaging (BLI) is a noninvasive method for measuring light output produced by the enzyme-catalyzed oxidation reaction of a substrate. The AkaBLI system, composed of AkaLumine-HCl and AkaLuc, provides a light source of sufficient strength to penetrate body walls, even in deep tissue areas.\(^13\) pcDNA3/Venus-Akaluc was obtained from RIKEN BioResource Research Center (catalog no. RDB15781). The nucleotide sequence of the synthetic construct AkaLuc gene for firefly luciferase mutant protein AkaLuc is available under the DNA Data Bank of Japan accession no. LC320664. For generation of the
Figure 1. PTC299 inhibits the proliferation of MDS cell lines. (A) Schematic representation of the pyrimidine synthesis pathway. CAD, carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase; CDA, cytidine deaminase; UMPS, UMP synthase. (B) Growth of HL-60 and THP-1 AML cells treated with the indicated concentrations of PTC299. The numbers of viable cells are shown as means ± SD (n = 3). ****P < .001 by a 1-way ANOVA. (C) Flow cytometric histograms showing CD11b expression levels on HL-60 and THP-1 cells treated with the indicated concentrations of PTC299 for 7 days. (D) Growth of MDS-L and SKM-1 MDS cells treated with the indicated concentrations of PTC299 for 9 days.
Lentiviral production and transduction

Recombinant mScarlet-P2A-Akaluc lentivirus was generated by transient cotransfection of HEK293T cells with CS-CDF-ubc-mScarlet-2A-Akaluc-PRE and the helper plasmids pMD2.G (Addgene #12259) as well as psPAX2 (Addgene #12260) using the polyethylenimine method. Culture supernatants were collected after 96 hours and filtered (22 μm), followed by concentration of the lentiviral particles by centrifugation at 40,000g for 4 hours.

Xenograft studies

All studies involving animals were performed in accordance with the institutional guidelines for the use of laboratory animals and approved by the Review Board for Animal Experiments of the University of Tokyo (approval ID PA18-42). Male NOD.Cg-PrkdcscidIl2rgtm1Sug/ShiJic (NOG) mice were purchased from CLEA Japan Inc (Tokyo, Japan). NOD.Cg-PrkdcscidIl2rgtm1Sug/ShiJic (NOG IL-3/GM-Tg) mice expressing human IL-3 and GM-CSF were purchased from the Central Institute for Experimental Animals (Kawasaki, Japan).14 SKM-1/Akaluc cells (2 × 10⁶ cells), which express the Akaluc gene, were inoculated into NOG mice irradiated at a dose of 0.5 Gy. One week after tumor inoculation, mice were randomly divided into 4 groups (5 mice per group) and treated with the indicated compounds. MDS-L/Akaluc cells (7.5 × 10⁶ cells) were inoculated into female NOG IL-3/GM-TG mice without any preconditioning. One week after tumor inoculation, mice were randomly divided into 3 groups (7 mice per group) and treated with the indicated compounds. One hundred microliters of 5 mM Akalumine-HCl (Wako) was injected intraperitoneally into mice just before the imaging analysis and mice under isoflurane anesthesia were imaged within 5 to 10 minutes after injection. The following conditions were used for the image acquisition: open for total bioluminescence, exposure time = 30 seconds, binning = 2, field of view = 25 × 25 cm, and f/stop = 1. In vivo photon counting was conducted with an IVIS system using Living Image 2.5 software (Xenogen).15 Mice were monitored until they became moribund, at which time they were sacrificed.

Primary MDS samples

Freshly isolated primary MDS cells were obtained from the BM aspirates or peripheral blood of 6 patients with MDS and 2 patients with MDS/AML. The control BM cells were obtained from 1 patient with early-stage lymphoma without BM invasion. All patients provided written informed consent according to institutional guidelines. The present study was approved by the institutional review board at the University of Tokyo and Chiba University (approval #30-47-B1002 and #844, respectively). BM-mononuclear cells (MNCs) were isolated using LyphoPrep (Cosmo Bio) and CD34⁺ cells were obtained from BM-MNCs using a CD34 MicroBead kit (Miltenyi Biotec). CD34⁺ cells were seeded into culture flasks in RPMI medium supplemented with 1% penicillin/streptomycin, 20% FBS, and 10 ng/mL of stem cell factor (SCF), TPO, IL-3, GM-CSF, and FLT3 ligand (BioLegend). The effects of PTC299 and decitabine in combination were evaluated using the MTS viability test (Promega) and colony-forming assay.

Figure 1. (continued) indicated concentrations of PTC299. The numbers of viable cells are shown as means ± SD (n = 3). *P < .05, **P < .01 by 1-way ANOVA. (E) Mean fluorescent intensity (MF) of CD38 on MDS-L and SKM-1 cells treated with the indicated concentrations of PTC299 for 7 days. Data are shown as means ± SD (n = 3), *P < .05, **P < .01, ***P < .001 by 1-way ANOVA. (F) MDS-L and SKM-1 cells were treated with PTC299 in the presence of an excess of uridine (100 μM) for 7 days. The numbers of viable cells are shown as means ± SD (n = 3). *P < .05, **P < .01, ***P < .001; ns, not significant by 1-way ANOVA. (G) MTS assays showing the viability of MDS-L and SKM-1 cells treated with the indicated doses of PTC299 with or without 100 μM uridine on day 7 of culture. Data represent mean ± SD (n = 4). **P < .01 by the Student t test.
patient with a complex karyotype and the MLL-AF9 fusion gene. PTC299 inhibited the proliferation of both MDS-L and SKM-1 cells (Figure 1D). However, PTC299 did not induce significant changes in the expression levels of CD11b, which had high basal expression, or morphology (data not shown). PTC299 only induced the dose-dependent upregulation of CD38 levels in MDS cell lines (Figure 1E). We performed a rescue experiment to confirm the specific inhibitory effects of PTC299 on the de novo pyrimidine synthesis pathway (Figure 1A). The growth inhibitory effects of PTC299 were completely prevented by the addition of excess of
exogenous uridine, which bypasses the requirement for de novo pyrimidine synthesis by feeding into the salvage pathway, thereby negating the need for DHODH (Figure 1A, F-G). These results indicate that PTC299 potently inhibits the growth of MDS cells, but does not strongly induce their differentiation, and that the effect on growth is DHODH dependent and not because of general cytotoxicity.

**PTC299 and DNA-demethylating agents exert synergistic cytotoxic effects**

The sensitivity of some of the MDS cell lines, such as MDS-L and SKM-1, to PTC299 was markedly less than AML cells. PTC299 did not reduce the viability of MDS-L cells by more than 50% (Figure 2A). Other cell lines including AML cells were more sensitive...
to PTC299 as demonstrated by the low concentrations of PTC299 required to inhibit cell viability by 50% (cytotoxic concentration; \( CC_{50} \)) (MDS-L, >1000 nM; SKM-1, 62.5 nM; TF-1, 2.0 nM; MOLM-13, 7.9 nM; THP-1, 28.7 nM; HL-60, 8.4 nM) (Figure 2A-B). Among MDS cell lines, MDS-L, which was derived from an MDS (not MDS/AML) patient, was the least sensitive to PTC299, suggesting that MDS cells may be less sensitive to PTC299 than AML cells.\(^{16}\) To enhance the therapeutic benefits of PTC299 on MDS cells, we investigated the possible synergism between PTC299 and decitabine, a first-line therapeutic agent in the

**Figure 4.** PTC299 downregulates c-MYC in MDS cells. (A) Venn diagram showing the overlap of down- (≤0.66-fold) or upregulated (≥1.5-fold) genes between MDS-L and SKM-1 cells treated with PTC299 relative to the DMSO control (left). Kyoto Encyclopedia of Genes and Genomes pathways enriched in overlapping genes (right) (B) GSEA plots showing the enrichment of MYC target genes in MDS-L (upper) and SKM-1 (lower) cells treated with PTC299 (left), DAC (center), and their combination (right) relative to control (Ctrl) cells. Normalized enrichment scores (NES), nominal \( P \) values (NOM), and false discovery rates (FDR) are indicated. (C-D) Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of c-MYC in MDS cells treated with the indicated doses of (C) PTC299 and (D) 30 nM PTC299, 200 nM DAC as a single agent or in combination for 48 hours. GAPDH was used to normalize the amount of input RNA. nd, not detected. Data are shown as the mean ± SD (\( n = 3 \)). (E) Immunoblotting of the extracts from MDS-L cells treated with PTC299 and/or DAC. (F) Growth of MDS-L cells with exogenous c-MYC expression was induced by adding 1 \( \mu \)g/mL doxycycline. (G) The proportions of cells at the indicated phases of cell cycle are shown. MDS-L cells with or without exogenous c-MYC were treated with PTC299 for 72 hours. BrdU was added to the culture 2 hours before the analysis. Data are shown as the mean ± SD (\( n = 3 \)). *\( P < .05 \), **\( P < .01 \), ***\( P < .001 \); ns, not significant by 1-way ANOVA.
treatment of MDS. We treated MDS-L and SKM-1 cells with increasing concentrations of PTC299 (0 to 240 nM) and decitabine (0 to 100 nM) as a single agent or in combination. After 5 days of culture, cells were analyzed by MTS assays. PTC299 and decitabine exerted synergistic cytotoxic effects in MDS-L cells at all concentrations tested, showing a very low combination index, which defines synergism when the calculated number is less than 1 (Figure 2C; supplemental Table 2). Another first-line agent, azacitidine, was effective in combination with PTC299 (Figure 2D). Brequinar, another DHODH inhibitor, also showed a synergistic effect with decitabine (Figure 2E). Apoptosis assays using Annexin V revealed that decitabine significantly, whereas PTC299 modestly, induced apoptosis in these cells (Figure 3A). Cell-cycle assays clearly showed that PTC299 induced intra-S-phase arrest (Figure 3B), similar to other DHODH inhibitors, whereas decitabine, which is incorporated into DNA in the S-phase, released intra-S-phase arrest by PTC299 when used in combination (Figure 3C).

Decitabine is a chemical analog of cytidine that has direct cytotoxicity and induces DNA hypomethylation by interfering with DNA methyltransferase. PTC299 decreases dCTP and dTTP by inhibiting de novo pyrimidine synthesis. Cells treated with PTC299 are starved of cytidine. We suspected that, under this condition, cells will incorporate more decitabine, which is incorporated into DNA (Figure 3D). To prove this hypothesis, we cultured MDS-L cells in the presence of 0, 100, and 200 nM decitabine for 24 hours with and without 30 nM PTC299. We then purified DNA from treated cells and conducted a liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis on the content of decitabine incorporated into DNA. One-step multienzyme digestion was used to release the DNA-bound drug following the protocol reported by Chilakala et al. Enzyme-released decitabine along with other mononucleosides were separated by an Atlantis Silica HILIC Column using high organic mobile phases and quantified by mass spectrometry using the multiple-reaction-monitoring mode. A stable heavy isotope of 2-deoxyctydine 15N3 was used as an internal standard. As expected, the amounts of decitabine incorporated were increased in a dose-dependent manner and enhanced twofold in the presence of PTC299 (Figure 3E).

PTC299 downregulates c-MYC in MDS cells
To understand the effects of PTC299 on the transcriptome and identify critical target genes, we performed an RNA-seq analysis of MDS-L and SKM-1 cells treated with 30 nM of PTC299 and 200 nM of decitabine as a single agent or in combination, and DMSO-treated control cells. We selected genes up- (≥1.5-fold) and downregulated (≤0.66-fold) in both MDS-L and SKM-1 cells upon the PTC299 treatment, and then performed the Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. The pyrimidine metabolism pathway was negatively enriched in the overlapping genes (Figure 4A). GSEA of RNA-seq data revealed that MYC target gene sets were negatively enriched with significance in PTC299- or decitabine-treated cells and cells treated in combination (Figure 4B). PTC299 treatment induced downregulation of MYC target genes, but not global gene expression in both MDS-L and SKM-1 cells (supplemental Figure 1), suggesting that MYC is one of the specific target genes downregulated by PTC299. Reverse transcriptase quantitative polymerase chain

Figure 4.(Continued).
reaction confirmed that the expression of c-MYC was downregulated after the treatment with single agents, which was further enhanced by the combination in both cell lines (Figure 4C-D). Similar results were obtained at protein levels (Figure 4E). To understand the impact of c-MYC downregulation on the cytotoxic effects of PTC299 in MDS cells, we conditionally overexpressed c-MYC in MDS-L cells using a Tet-on lentivirus system. Exogenous c-MYC largely prevented PTC299-mediated growth suppression of MDS-L cells (Figure 4F), which was accompanied by a decrease in S-phase cells and an increase in G2/M cells (Figure 4G).

These results suggest that sustained c-MYC expression conferred resistance to PTC299 on MDS-L cells.

PTC299 and decitabine combination exerts synergistic effects on primary MDS cells

We investigated the efficacy of the combined treatment of PTC299 and decitabine in primary cells derived from 4 MDS patients and an MDS/AML patient. CD34+ hematopoietic stem/progenitor cells were purified from the BM MNCs of MDS patients by a column...
**Figure 6.** PTC299 and decitabine exert synergistic effects in the xenograft MDS model. (A) Schematic representation of the xenograft MDS model using NOG mice. Bioluminescence signals in NOG mice infused with $2 \times 10^6$ SKM-1/Akaluc cells via the tail vein. NOG mice were irradiated at a dose of 0.5 Gy just before transplantation. Starting on day 12 posttransplantation, recipient mice received vehicle once a day (QD) orally every day ($n=5$), 10 mg/kg of PTC299 QD orally every day ($n=5$), 0.3 mg/kg of DAC intraperitoneal 3 times per week ($n=5$), and PTC299 and DAC ($n=5$) for 3 weeks. (B) Quantification of photon counts from SKM-1/Akaluc cells in xenograft MDS mice. Bioluminescence signals taken by a photon-counting analyzer, are shown in the left panel. Akaluc activity in treated mice was detected weekly. A Kaplan-Meier survival...
PTC299 and decitabine exert synergistic effects in the xenograft MDS model

We assessed the efficacy of PTC299 in xenograft mouse models of MDS. To precisely monitor the tumor burden in mice, we took advantage of the AkalucBLI system, composed of AkaLumine-HCI and Akaluc, which improved performance by a factor of 100 to 1000 over the conventional bioluminescence imaging system composed of d-luciferin and firefly luciferase. AkaBLI provided a light source of sufficient strength to penetrate body walls, even in deep tissue areas, thereby allowing the noninvasive visualization of single cells deep inside freely moving animals.13 SKM-1 and MDS-L cells were transduced with the Akaluc gene using lentiviruses and selected by mScarlet expression as a marker. SKM-1/Akaluc (2 × 10⁶) and MDS-L/Akaluc cells (7.5 × 10⁵) were intravenously inoculated into NOG mice irradiated at a dose of 0.5 Gy and NOG mice expressing human IL-3 and GM-CSF (NOG IL-3/GM-TG)14 without any preconditioning, respectively. Recipient mice were then treated with PTC299 and decitabine as a single agent or in combination (Figure 6A,C). The tumor burden was monitored by bioluminescence signals in vivo imaging assays and bioluminescence signals in mice were detected weekly. SKM-1 cells, which exhibit MDS-AML-like features, rapidly expanded and induced lethal diseases in NOG mice. PTC299 and decitabine both exerted mild inhibitory effects on the growth of SKM-1 cells as single agents, but significantly suppressed their growth in combination, resulting in the significant extension of survival of recipient mice (Figure 6B). In contrast to SKM-1 cells, MDS-L cells, which retain MDS-like features, expand very slowly in NOG IL-3/GM-TG mice. PTC299 and decitabine inhibited the growth of MDS-L cells as single agents, although their effects were not statistically significant (Figure 6C-E; supplemental Figure 2). In contrast, PTC299 and decitabine significantly suppressed the growth of MDS-L cells in combination (Figure 6D-E; supplemental Figure 2). These results clearly indicate that PTC299 enhances the therapeutic efficacy of decitabine against MDS cells. Treatment by single agents or combination did not significantly affect the body weight or blood cell counts of NOG mice (Figure 6F), suggesting that the toxicity of PTC299 and/or decitabine was tolerable.

Discussion

In the present study, we investigated the therapeutic efficacy of PTC299, a novel DHODH inhibitor, on MDS cells. We showed that PTC299 exerted antiproliferative effects on MDS cells similar to AML cells. Of note, MDS cell lines that retained the features of MDS before leukemic transformation16 were less sensitive to PTC299 than AML cells in terms of growth inhibition and the induction of differentiation, suggesting that MDS cells are less dependent on the de novo pyrimidine synthesis pathway than AML cells. The expression levels of DHODH in MDS and AML patients are comparable to those in healthy controls (GEO database and Beat AML data viewer [Vizome]). Therefore, the levels of DHODH may not be crucial in terms of efficacy of DHODH inhibitor. However, PTC299 synergized with DNA-demethylating agents in the treatment of MDS cells. Mechanistically, we demonstrated that PTC299 enhanced the incorporation of decitabine in MDS cells by an LC-MS/MS analysis. Cells treated with PTC299 are starved of cytokine, resulting in intra-S-phase arrest. Under this condition, MDS cells may have incorporated more decitabine, an analog of cytidine, instead of cytidine. The incorporation of decitabine was previously shown to be directly related to treatment effect.27 Therefore, the enhancement of decitabine incorporation by DHODH inhibitors represents a novel combination therapy that enhances the cytotoxic effects of decitabine. Decitabine and azacitidine not only exhibit cytotoxicity, but also hypomethylating activity. DNA hypomethylation is observed at lower concentrations rather than at higher concentrations, the latter of which is associated with direct cytotoxicity through DNA double-strand breaks.28 The clinically used dosages of decitabine and azacitidine mainly focus on their hypomethylating activity.29 We chose to use low-dose decitabine in vivo experiments to match the clinical dose.30 PTC299 efficiently synergized with low doses of decitabine in MDS xenograft model mice and suppressed disease progression. Therefore, we postulate that PTC299 combined with hypomethylating agents would be effective even at the clinical dosage.

We previously referred to the possible synergism between PTC299 and cytarabine (AraC), a deoxycytidine analog used as a standard chemotherapeutic agent to treat AML. The increased activity of the combination of AraC with PTC299 may reflect the more efficient incorporation of AraC into DNA because of a reduction in the levels of competing endogenous pyrimidine nucleotides, as we demonstrated with decitabine in the present study. Although combination therapy with AraC may be a promising option for various types of
hematological malignancies, eligible patients may be limited due to enhanced cytotoxic effects because high-dose AraC therapy is only accessible and well tolerated by a small number of patients. In contrast, hypomethylating agents are widely used in clinical settings, such as for MDS and elderly AML patients, and side effects are generally considered to be tolerable. PTC299 does not inhibit the proliferation of normal cells, including hematopoietic stem cells at concentrations 1000-fold greater than its 50% inhibitory concentration in tumor cells in vitro and was shown to be generally well tolerated in clinical trials. Therefore, PTC299 with hypomethylating agents might be widely applied to the treatment of AML and MDS, including older aged patients, because of a tolerable safety profile.

We also determined that the effect of PTC299 was at least partly the result of downregulation of c-MYC. PTC299 and decitabine both downregulated c-MYC, and their combination was additive. Transfection of MDS cells with c-MYC largely attenuated the growth inhibitory effects of PTC299. The gene expression profiles of CD34+ cells from MDS patients showed c-MYC as one of the most upregulated genes in these patients. The amplification of MYC at 8q24.21 has also been reported at low frequencies in MDS including patients with trisomy 8, in which c-MYC expression was upregulated and c-MYC inhibition induced the specific loss of trisomy 8 cell viability in cultures. These findings suggest that c-MYC is also a therapeutic target in MDS, similar to AML. Other DHODH inhibitors, Brequin and BAY 2402234, also downregulate c-MYC, indicating that downregulation of c-MYC is not an off-target effect of PTC299. The mechanisms by which PTC299 downregulates c-MYC remain unclear. This issue may be an important next step in studying the mechanisms underlying the cytotoxic effects of DHODH inhibition not directly associated with the suppression of pyrimidine synthesis. The impact of c-MYC downregulation in AML cells is another issue to be examined to obtain a deeper understanding of the therapeutic efficacy of PTC299 for MDS, as a precursor to AML, and AML.

**Acknowledgments**

The authors thank Tomoyuki Yamaguchi for providing Tet-on c-Myc vector and Mikako Kuribayashi for illustrating the mouse picture. The super-computing resource was provided by the Human Genome Center, the Institute of Medical Science, the University of Tokyo. This work was supported in part by Grants-in-Aid for Scientific Research (#19H05653) and Scientific Research on Innovative Areas “Replication of Non-Genomic Codes” (#19H05746) from MEXT, Japan, and grants from the Takeda Science Foundation and the Princess Takamatsu Cancer Research Fund.

**Author contributions**

K.K. and A.I. designed this study; K.K. performed experiments, analyzed data, and actively wrote the manuscript; Y.N., S. Kaito, D.S., Y.N.-T., S. Koide, W.K., M.Y., C.Z., and N.M. performed experiments and analyzed data; M.O. analyzed next-generation sequencing data; K.I., S.Y., S.I., A.M., H.J.B., K.I., S.Y., and R.I. set up the xenograft mouse model; S.I. and A.M. developed and provided the AkaBLI system; K.T. developed and provided the MDS-L cell line; W.L., J.S., and M.W. developed and supplied PTC299; E.S. and K.Y. conceptualized the research and edited the manuscript; and A.I. conceived of and directed the project, secured funding, and actively wrote the manuscript.

Conflict-of-interest disclosure: W.L., J.S., and M.W. are employed by PTC Therapeutic and have received salary compensation for time, effort, and hold or held financial interest in the company. The remaining authors declare no competing financial interests.

**ORCID profiles:** K.K., 0000-0001-6140-3135; M.Y., 0000-0001-9459-4329; H.J.B., 0000-0003-3058-9859; S.I., 0000-0003-7375-1504; E.S., 0000-0002-7254-1928; A.I., 0000-0001-9410-8992.

Correspondence: Atsushi Iwama, Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan; e-mail: 03aiwama@ims.u-tokyo.ac.jp.

**References**

1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol*. 2009;10(3):223-232.

2. Platzbecker U. Treatment of MDS. *Blood*. 2019;133(10):1096-1107.

3. Sykes DB, Kfoury YS, Mercier FE, et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. *Cell*. 2016;167(1):171-186.e15.

4. Sugiuira Y, Fujioka S, Yoshida S. Biosynthesis of pyrimidine nucleotides in human leukemic cells. *Jpn J Cancer Res*. 1986;77(7):664-673.

5. Lane AN, Fan TW. Regulation of mammalian nucleotide metabolism and biosynthesis. *Nucleic Acids Res*. 2015;43(4):2466-2485.

6. Baumann P, Mandl-Weber S, Völkl A, et al. Dihydroorotate dehydrogenase inhibition not directly associated with the suppression of pyrimidine synthesis. The impact of c-MYC downregulation in AML cells is another issue to be examined to obtain a deeper understanding of the therapeutic efficacy of PTC299 for MDS, as a precursor to AML, and AML.

**References**

1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol*. 2009;10(3):223-232.

2. Platzbecker U. Treatment of MDS. *Blood*. 2019;133(10):1096-1107.

3. Sykes DB, Kfoury YS, Mercier FE, et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. *Cell*. 2016;167(1):171-186.e15.

4. Sugiuira Y, Fujioka S, Yoshida S. Biosynthesis of pyrimidine nucleotides in human leukemic cells. *Jpn J Cancer Res*. 1986;77(7):664-673.

5. Lane AN, Fan TW. Regulation of mammalian nucleotide metabolism and biosynthesis. *Nucleic Acids Res*. 2015;43(4):2466-2485.

6. Baumann P, Mandl-Weber S, Völkl A, et al. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. *Mol Cancer Ther*. 2009;8(2):366-375.

7. Cody R, Stewart D, DeForni M, et al. Multicenter phase II study of brequinar sodium in patients with advanced breast cancer. *Am J Clin Oncol*. 1993;16(6):526-528.

8. Fitzpatrick LR, Small JS, Doblothero F, Ammendola A. Vidofludimous inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. *J Pharmacol Exp Ther*. 2012;342(3):850-860.

9. Cao L, Weetall M, Bombard J, et al. Discovery of novel small molecule inhibitors of expression in tumor cells using a cell-based high throughput screening platform. *PLoS One*. 2016;11(12):e0168366.
10. Cao L, Weetall M, Trotta C, et al. Targeting of hematologic malignancies with PTC299, a novel potent inhibitor of dihydroorotate dehydrogenase with favorable pharmaceutical properties. *Mol Cancer Ther*. 2019;18(1):3-16.

11. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. *Cancer Res*. 2010;70(2):440-446.

12. Yamaguchi T, Hanamaki S, Kamiya A, et al. Development of an all-in-one inducible lentiviral vector for gene specific analysis of reprogramming. *PLoS One*. 2012;7(7):e41007.

13. Iwano S, Sugiyama M, Hama H, et al. Single-cell bioluminescence imaging of deep tissue in freely moving animals. *Science*. 2018;359(6378):935-939.

14. Ito R, Takahashi T, Katano I, et al. Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice. *J Immunol*. 2013;191(6):2890-2899.

15. Yanagihara K, Takigahira M, Takeshita F, et al. A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination. *Cancer Res*. 2006;66(15):7532-7539.

16. Drexler HG, Dirks WG, Macleod RA. Many are called MDS cell lines: one is chosen. *Leuk Res*. 2008;33(8):1011-1016.

17. Matsuoka A, Tochigi A, Kishimoto M, et al. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. *Leukemia*. 2010;24(4):748-755.

18. Tohyama K, Tsutani H, Ueda T, Nakamura T, Yoshida Y. Establishment and characterization of a novel myeloid cell line from the bone marrow of a patient with the myelodysplastic syndrome. *Br J Haematol*. 1994;87(2):235-242.

19. Kida JI, Tsujioka T, Suemori SI, et al. An MDS-derived cell line and a series of its sublines serve as an in vitro model for the leukemic evolution of MDS. *Leukemia*. 2018;32(8):1846-1850.

20. Starczynowski DT, Kuchenbauer F, Arigropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. *Nat Med*. 2010;16(1):49-58.

21. Körnke J, Fink EC, Hollenbach PW, et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. *Nature*. 2015;523(7559):183-188.

22. Nakagawa T, Saitoh T, Imoto S, et al. Loss of multiple point mutations of RAS genes associated with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome. *Br J Haematol*. 1991;77(2):250-252.

23. Kitamura T, Tange T, Terasawa T, et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. *J Cell Physiol*. 1989;140(2):323-334.

24. Matsuo Y, MacLeod RA, Uphoff CC, et al. Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). *Leukemia*. 1997;11(9):1469-1477.

25. Christian S, Merz C, Evans L, et al. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. *Leukemia*. 2019;33(10):2403-2415.

26. Ladds MJGW, van Leeuwen IMM, Drummond CJ, et al. A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage [published correction appears in *Nat Commun*. 2018;9(1):2071]. *Nat Commun*. 2018;9(1):1107.

27. Chilakala S, Feng Y, Li L, et al. Tracking decitabine incorporation into malignant myeloid cell DNA in vitro and in vivo by LC-MS/MS with enzymatic digestion. *Sci Rep*. 2019;9(1):4558.

28. Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. *PLoS One*. 2010;5(2):e9001.

29. Stresemann C, Bokelmann I, Mahlknecht U, Lyko F. Azacytidine causes complex DNA methylation responses in myeloid leukemia. *Mol Cancer Ther*. 2008;7(9):2988-3005.

30. Yu G, Wu Y, Wang W, et al. Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment [published correction appears in *Cell Mol Immunol*. 2020;17(1):111-112]. *Cell Mol Immunol*. 2019;16(4):401-409.

31. Mayer RJ, Davis RB, Schiffer CA, et al; Cancer and Leukemia Group B. Intensive postremission chemotherapy in adults with acute myeloid leukemia. *N Engl J Med*. 1994;331(14):896-903.

32. Weetall M, Davis T, Elfring G, et al. Phase 1 study of safety, tolerability, and pharmacokinetics of PTC299, an inhibitor of stress-regulated protein translation. *Clin Pharmacol Drug Dev*. 2016;5(4):296-305.

33. Vasikova A, Belickova M, Budinska E, Cermak J. A distinct expression of various gene subsets in CD34+ cells from patients with early and advanced myelodysplastic syndrome. *Leuk Res*. 2010;34(12):1566-1572.

34. Sloand EM, Pfannes L, Chen G, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. *Blood*. 2007;109(6):2399-2405.

35. Delgado MD, Albajar M, Gomez-Casares MT, Batlle A, León J. MYC oncogene in myeloid neoplasias. *Clin Transl Oncol*. 2013;15(2):87-94.

36. Dorasamy MS, Choudhary B, Nellore K, Subramanya H, Wong PF. Dihydroorotate dehydrogenase inhibitors target c-Myc and arrest melanoma, myeloma and lymphoma cells at S-phase. *J Cancer*. 2017;8(15):3086-3098.